Abstract 641P
Background
Approved immune checkpoint inhibitors (ICI) have little to no benefit in patients (pts) with pMMR/MSS mCRC. Several combination strategies to overcome intrinsic resistance have failed. Prostaglandin E2, through its receptor 4 (EP4), is a major contributor to immunosuppression in the tumor microenvironment and blockade of this pathway may sensitize cold tumors to ICI. In preclinical models, the EP4 antagonist CR6086 significantly enhanced the activity of PD-1 blockade, prompting this ongoing phase I/II study of CR6086 added to the anti-PD-1 balstilimab in pMMR/MSS chemorefractory mCRC.
Methods
Adult pts with pMMR/MSS mCRC, ECOG PS ≤1 and previous exposure to fluoropyrimidines, oxaliplatin and irinotecan, received oral CR6086 (30, 90 or 180 mg twice daily) plus balstilimab (3 mg/kg every 2 weeks) until disease progression, unacceptable toxicity or death. Primary endpoints are safety and disease control rate (DCR) per RECIST 1.1. Secondary endpoints include objective response rate (ORR), duration of response, progression-free and overall survival (PFS, OS). Exploratory endpoints include tissue and blood biomarkers.
Results
Twenty-eight pts were treated and 8 are still ongoing. Median age was 59 (interquartile range [IQR]: 54-68) years and 54% were men; median prior treatment lines was 4 (IQR: 3-5). No dose-limiting toxicities were observed. CR6086-related AEs were grade 1 (G1), except for a serious G4 duodenal ulcer which led to consideration of proton pump inhibitors prophylaxis in all pts. Balstilimab-related AEs were ≤G2 and one was serious (pneumonitis). Three pts had partial response (all ongoing at 15, 8, and 6 months) and 11 had stable disease, with an ORR of 11% and a DCR of 50% (8% and 25% in the 12 pts with liver metastases). At a median follow-up of 6.4 months (IQR 5.3-8.4), median PFS and OS were 2 (95% CI, 1.7–3.6) and 11.3 (95% CI, 8.8–not reached) months, respectively. Translational analyses are ongoing.
Conclusions
CR6086 combined with balstilimab was well tolerated and achieved durable responses in pMMR/MSS mCRC. Expansion in other gastrointestinal tumours and further clinical development in pMMR/MSS mCRC are ongoing.
Clinical trial identification
NCT05205330.
Editorial acknowledgement
Legal entity responsible for the study
Rottapharm Biotech Srl, Italy.
Funding
Rottapharm Biotech Srl, Italy.
Disclosure
F. Pietrantonio: Financial Interests, Personal, Advisory Board: Amgen, Merck Serono, MSD, Bayer, Organon, Astellas; Financial Interests, Personal, Invited Speaker: Amgen, Merck-Serono, Bristol Myers Squibb, Lilly, Servier, Bayer, Pierre Fabre, AstraZeneca, Astellas; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb, AstraZeneca, Incyte, Agenus. F. Morano: Financial Interests, Personal, Invited Speaker: Servier, Pierre Fabre, Lilly; Financial Interests, Institutional, Research Grant: Incyte. M. Niger: Financial Interests, Personal, Other, consultant: EMD Serono, Incyte, MSD Italia; Financial Interests, Personal, Advisory Board, consultant: Basilea Pharmaceutica; Financial Interests, Personal, Advisory Board: AstraZeneca, Taiho; Financial Interests, Personal, Writing Engagement: Sandoz, Medpoint SRL, Incyte, Servier; Financial Interests, Personal, Invited Speaker: Incyte, Accademia della Medicina; Financial Interests, Personal, Other, travel expences for meetings: AstraZeneca. F. Ghelardi: Non-Financial Interests, Member: AIOM. All other authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11